Abstract library

574 results for "support group".
#2049 Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups?
Introduction: Neuroendocrine tumors (pNETs) are the second most common neoplasm. Most of the pNETs are diagnosed at later stages among those patients who are underprivileged. The diagnosis and treatment of neuroendocrine tumor is a continuous emotional distress for both patient and their family.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zai S S A
#2296 First Patient Survey about Tumor - Associated Fatigue in NEN
Introduction: Tumor-associated fatigue (TrF) is a debilitating condition occurring during the course of the tumor disease, and even ongoing after all tumor specific therapies are completed. The syndrome consists of chronic fatigue, sleep disturbances, severe pain, brain-fog and is underestimated by both, patients and doctors. Diagnosis is made according to the criteria by Cella (Cella 2001), although it is felt not to be sufficient.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PD Dr. Patricia Grabowski
#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Grietje Bouma
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Takuji Okusaka
Authors: Okusaka T, Ito T, Ikeda M, Tajima T, ...
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#1885 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with a neuroendocrine tumour (NET) frequently experience physical and psychosocial complaints. Novel strategies to provide information to optimize supportive care in these patients are of interest.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#210 Clinical Characteristics of the 5,160 Patients Included in the French Database of the French Endocrine Tumor Group (GTE)
Introduction: An endocrine tumor database was initiated in 2005 by the French endocrine tumor group (GTE). Today, it comprises 5,160 patients, 70% of whom were diagnosed from 2000.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Françoise Borson-Chazot
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1502 Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Rodney Pommier
#1694 Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)
Introduction: siNETs are notoriously difficult to diagnose, especially in an early stage.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD PhD Magnus Kjellman